The world is currently experiencing a huge challenge which has affected all the industries and markets. Few markets have experienced a high growth in their demand while others have faced a downfall. The extent of growth or drop in the market statistics of different industries by COVID 19 plays an important role in how the future of businesses will shape up in the near future. We at Value Market Research provide you with an impact analysis of COVID 19 on this market with its latest update in the purchased version of the report.
Global Benign Prostatic Hyperplasia (BPH) And Prostate Treatment Market Report By Product (Alpha Blockers, 5-Alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitors And Others), Therapy (Monodrug Therapy And Combination Therapy) And By Regions - Industry Trends, Size, Share, Growth, Estimation And Forecast, 2020-2027
ID:VMR11210343
July 2021
Report Formats:
Global Benign Prostatic Hyperplasia (BPH) and Prostate Treatment Market Overview
Benign prostatic hyperplasia (BPH) is the medical condition typically observed in old-aged men characterized by enlargement of the prostate gland resulting in squeezing of the urethra. BPH can cause problems in the urinary bladder, kidney, and urinary tract. It is often treated with prescribed doses of alpha-blockers, 5-alpha reductase, or a combination of other drugs. For severe conditions, minimally invasive or laser therapies are also performed. The number of men seeking treatment for benign prostatic hyperplasia (BPH) is expected to rise in the coming years due to the growing aging male population and the increasing prevalence of obesity, cardiovascular diseases, and erectile dysfunction. BPH is a common condition in aging men and the most common cause of lower urinary tract symptoms. The prevalence of BPH rises after 40 years, with a prevalence of 8% to 60% at age 90 years. As per United Nations, the number of older persons is growing faster than the younger age groups. The global population aged over 80 years is projected to triple, increasing from 137 million in 2017 to 425 million in 2050. Obesity affects the geriatric population in parallel to that of the general population. The prevalence of obesity in the older population has been rising and now poses a major global threat in developed and developing countries. All of these will contribute to the growing prevalence of BPH, thus therapeutics.
The rise in awareness regarding urological diseases contributes to the growth of the benign prostatic hyperplasia treatment market. The growing preference for advanced treatment such as transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), transurethral microwave therapy (TUMT), and other minimally invasive techniques are also projected to foster the market growth during the timespan. Even if BPH is treated with drugs and surgeries, it does come with some side effects. Common side effects include dizziness, orthostatic hypotension, retrograde ejaculation, and rhinitis. Surgeries' side effects include pain, problems urinating, and other infections. This may hinder the market growth.
The global benign prostatic hyperplasia treatment market is highly fragmented. Abbott Laboratories, Allergan plc, Astellas Pharma, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Boehringer Ingelheim Pharma GmbH & Co. KG, Merck & Co., Inc., Pfizer, Inc., Sanofi, and Teva Pharmaceutical Industries Limited are key players associated with the market. Key companies are adopting merger & acquisition strategies and joint ventures to gain a more significant share in the overall market. Several companies are spending in R&D for the exploration of better treatment.
 and Prostate Treatment Market.webp)
In this research report, the global Benign Prostatic Hyperplasia (BPH) and Prostate Treatment market is segmented by therapy and region.
Analysis, By Therapy:
By therapy, the global benign prostatic hyperplasia therapeutics market is segmented into drugs and surgeries. The drug segment occupied a major share in 2020. Drugs alone are known to be more effective. Drug therapy is growing due to its high effectiveness, superior symptomatic benefit, and a significant reduction in adverse events. Among drugs, the alpha-blocker segment acquired a major share in the market and is expected to stay dominant throughout the forecast period, owing to high preference, superior therapeutic action, and availability of many alpha-blockers drugs. Alpha-blockers work by relaxing the prostate and bladder neck muscle and allows urine to flow more easily. The surgeries segment is also projected to grow significantly due to the growing severity of the condition and failure of drug treatment.
Analysis, By Region
Geographically, the global benign prostatic hyperplasia treatment market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is a dominant region in the global market, while the Asia-Pacific region is anticipated to grow faster during the forecast period. North America is expected to grow with the rising prevalence of benign prostatic hyperplasia, greater access to treatment. Also, the region is home to many market players and is blessed with skilled expertise. Asia Pacific growth is driven by factors including a high male population base, increased disposable income, and enhanced patient awareness about benign prostatic hyperplasia.
Market Segmentation covered in the Report:
By Therapy
By Region
METHODOLOGY
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.
Benign prostatic hyperplasia (BPH) is the medical condition typically observed in old-aged men characterized by enlargement of the prostate gland resulting in squeezing of the urethra. BPH can cause problems in the urinary bladder, kidney, and urinary tract. It is often treated with prescribed doses of alpha-blockers, 5-alpha reductase, or a combination of other drugs. For severe conditions, minimally invasive or laser therapies are also performed. The number of men seeking treatment for benign prostatic hyperplasia (BPH) is expected to rise in the coming years due to the growing aging male population and the increasing prevalence of obesity, cardiovascular diseases, and erectile dysfunction. BPH is a common condition in aging men and the most common cause of lower urinary tract symptoms. The prevalence of BPH rises after 40 years, with a prevalence of 8% to 60% at age 90 years. As per United Nations, the number of older persons is growing faster than the younger age groups. The global population aged over 80 years is projected to triple, increasing from 137 million in 2017 to 425 million in 2050. Obesity affects the geriatric population in parallel to that of the general population. The prevalence of obesity in the older population has been rising and now poses a major global threat in developed and developing countries. All of these will contribute to the growing prevalence of BPH, thus therapeutics.
According to Value Market Research, the global Benign Prostatic Hyperplasia (BPH) and Prostate Treatment market size was valued at about USD 10.51 billion in 2020 and is estimated to grow at a CAGR of around 5.5 % during the forecast period 2021 to 2027.
The rise in awareness regarding urological diseases contributes to the growth of the benign prostatic hyperplasia treatment market. The growing preference for advanced treatment such as transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), transurethral microwave therapy (TUMT), and other minimally invasive techniques are also projected to foster the market growth during the timespan. Even if BPH is treated with drugs and surgeries, it does come with some side effects. Common side effects include dizziness, orthostatic hypotension, retrograde ejaculation, and rhinitis. Surgeries' side effects include pain, problems urinating, and other infections. This may hinder the market growth.
The global benign prostatic hyperplasia treatment market is highly fragmented. Abbott Laboratories, Allergan plc, Astellas Pharma, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Boehringer Ingelheim Pharma GmbH & Co. KG, Merck & Co., Inc., Pfizer, Inc., Sanofi, and Teva Pharmaceutical Industries Limited are key players associated with the market. Key companies are adopting merger & acquisition strategies and joint ventures to gain a more significant share in the overall market. Several companies are spending in R&D for the exploration of better treatment.
In this research report, the global Benign Prostatic Hyperplasia (BPH) and Prostate Treatment market is segmented by therapy and region.
Analysis, By Therapy:
By therapy, the global benign prostatic hyperplasia therapeutics market is segmented into drugs and surgeries. The drug segment occupied a major share in 2020. Drugs alone are known to be more effective. Drug therapy is growing due to its high effectiveness, superior symptomatic benefit, and a significant reduction in adverse events. Among drugs, the alpha-blocker segment acquired a major share in the market and is expected to stay dominant throughout the forecast period, owing to high preference, superior therapeutic action, and availability of many alpha-blockers drugs. Alpha-blockers work by relaxing the prostate and bladder neck muscle and allows urine to flow more easily. The surgeries segment is also projected to grow significantly due to the growing severity of the condition and failure of drug treatment.
Analysis, By Region
Geographically, the global benign prostatic hyperplasia treatment market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is a dominant region in the global market, while the Asia-Pacific region is anticipated to grow faster during the forecast period. North America is expected to grow with the rising prevalence of benign prostatic hyperplasia, greater access to treatment. Also, the region is home to many market players and is blessed with skilled expertise. Asia Pacific growth is driven by factors including a high male population base, increased disposable income, and enhanced patient awareness about benign prostatic hyperplasia.
Market Segmentation covered in the Report:
By Therapy
- Drug Treatment (Alpha Blockers, 5-Alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitors, Others)
- Surgical Treatment (Transurethral Resection of the Prostate (TURP), Transurethral Microwave Thermotherapy (TUMT), Transurethral Needle Ablation of the Prostate (TUNA), Laser Therapy, Prostatic Stenting, UroLift Therapy, Rezûm Therapy, Other)
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
METHODOLOGY
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.
1 . PREFACE
1.1. Report Description
1.1.1. Objective
1.1.2. Target Audience
1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Market Research Process
1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
2.1. Highlights of Market
2.2. Global Market Snapshot
3 . BENIGN PROSTATIC HYPERPLASIA (BPH) AND PROSTATE TREATMENT – INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter’s Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 By Therapy
3.7.2 By Region
4 . VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1. List of Raw Materials
4.2.2. Raw Material Manufactures List
4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1. Direct Marketing
4.4.2. Indirect Marketing
4.4.3. Marketing Channel Development Trend
5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK
5.1. Impact Analysis of Covid-19 Outbreak
5.1.1. Direct Impact on Production
5.1.2. Supply Chain and Market Disruption
5.1.3. Financial Impact on Firms and Financial Markets
5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
5.3. Market: Pre V/S Post COVID-19
5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
5.5. COVID-19: Micro and Macro Factor Analysis
6 . GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) AND PROSTATE TREATMENT MARKET ANALYSIS BY THERAPY
6.1 Overview by Therapy
6.2 Historical and Forecast Data
6.3 Analysis by Therapy
6.4 Drug Treatment Market by Regions
6.5 Surgical Treatment Market by Regions
7 . GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) AND PROSTATE TREATMENT MARKET ANALYSIS BY GEOGRAPHY
7.1. Regional Outlook
7.2. Introduction
7.3. North America
7.3.1. Overview, Historic and Forecast Data
7.3.2. North America By Segment
7.3.3. North America By Country
7.3.4. United State
7.3.5. Canada
7.3.6. Mexico
7.4. Europe
7.4.1. Overview, Historic and Forecast Data
7.4.2. Europe by Segment
7.4.3. Europe by Country
7.4.4. United Kingdom
7.4.5. France
7.4.6. Germany
7.4.7. Italy
7.4.8. Russia
7.4.9. Rest Of Europe
7.5. Asia Pacific
7.5.1. Overview, Historic and Forecast Data
7.5.2. Asia Pacific by Segment
7.5.3. Asia Pacific by Country
7.5.4. China
7.5.5. India
7.5.6. Japan
7.5.7. South Korea
7.5.8. Australia
7.5.9. Rest Of Asia Pacific
7.6. Latin America
7.6.1. Overview, Historic and Forecast Data
7.6.2. Latin America by Segment
7.6.3. Latin America by Country
7.6.4. Brazil
7.6.5. Argentina
7.6.6. Peru
7.6.7. Chile
7.6.8. Rest of Latin America
7.7. Middle East & Africa
7.7.1. Overview, Historic and Forecast Data
7.7.2. Middle East & Africa by Segment
7.7.3. Middle East & Africa by Country
7.7.4. Saudi Arabia
7.7.5. UAE
7.7.6. Israel
7.7.7. South Africa
7.7.8. Rest Of Middle East And Africa
8 . COMPETITIVE LANDSCAPE OF THE BENIGN PROSTATIC HYPERPLASIA (BPH) AND PROSTATE TREATMENT COMPANIES
8.1. Benign Prostatic Hyperplasia (Bph) And Prostate Treatment Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments
9 . COMPANY PROFILES OF BENIGN PROSTATIC HYPERPLASIA (BPH) AND PROSTATE TREATMENT INDUSTRY
9.1. Company Share Analysis
9.2. Market Concentration Rate
9.3. Abbott Laboratories
9.3.1. Company Overview
9.3.2. Financials
9.3.3. Products
9.3.4. Recent Developments
9.4. Allergan plc
9.4.1. Company Overview
9.4.2. Financials
9.4.3. Products
9.4.4. Recent Developments
9.5. Astellas Pharma, Inc.
9.5.1. Company Overview
9.5.2. Financials
9.5.3. Products
9.5.4. Recent Developments
9.6. Eli Lilly and Company
9.6.1. Company Overview
9.6.2. Financials
9.6.3. Products
9.6.4. Recent Developments
9.7. GlaxoSmithKline plc
9.7.1. Company Overview
9.7.2. Financials
9.7.3. Products
9.7.4. Recent Developments
9.8. Boehringer Ingelheim Pharma GmbH & Co. KG
9.8.1. Company Overview
9.8.2. Financials
9.8.3. Products
9.8.4. Recent Developments
9.9. Merck & Co., Inc.
9.9.1. Company Overview
9.9.2. Financials
9.9.3. Products
9.9.4. Recent Developments
9.10. Pfizer, Inc.
9.10.1. Company Overview
9.10.2. Financials
9.10.3. Products
9.10.4. Recent Developments
9.11. Sanofi
9.11.1. Company Overview
9.11.2. Financials
9.11.3. Products
9.11.4. Recent Developments
9.12. Teva Pharmaceutical Industries Limited
9.12.1. Company Overview
9.12.2. Financials
9.12.3. Products
9.12.4. Recent Developments
*Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies
LIST OF TABLES
- Market Snapshot
- Drivers : Impact Analysis
- Restraints : Impact Analysis
- List of Raw Material
- List of Raw Material Manufactures
- List of Potential Buyers
- COVID-19 Impact Analysis by Production, Import, Export and Demand
- Pre V/S Post COVID-19
- Estimated Impact Of The Coronavirus (Covid-19) Epidemic
- COVID-19: Micro and Macro Factor Analysis
- Analysis by Therapy (USD MN)
- Drug Treatment Market by Geography (USD MN)
- Surgical Treatment Market by Geography (USD MN)
- Global Benign Prostatic Hyperplasia (Bph) And Prostate Treatment Market by Geography (USD MN)
- North America Market Analysis (USD MN)
- United State Market Analysis (USD MN)
- Canada Market Analysis (USD MN)
- Mexico Market Analysis (USD MN)
- Europe Market Analysis (USD MN)
- Europe Market Estimate by Country (USD MN)
- United Kingdom Market Analysis (USD MN)
- France Market Analysis (USD MN)
- Germany Market Analysis (USD MN)
- Italy Market Analysis (USD MN)
- Russia Market Analysis (USD MN)
- Spain Market Analysis (USD MN)
- Rest of Europe Market Analysis (USD MN)
- Asia Pacific Market Analysis (USD MN)
- China Market Analysis (USD MN)
- Japan Market Analysis (USD MN)
- India Market Analysis (USD MN)
- South Korea Market Analysis (USD MN)
- Australia Market Analysis (USD MN)
- Rest of Asia Pacific Market Analysis (USD MN)
- Latin America Market Analysis (USD MN)
- Brazil Market Analysis (USD MN)
- Argentina Market Analysis (USD MN)
- Peru Market Analysis (USD MN)
- Chile Market Analysis (USD MN)
- Rest of Latin America Market Analysis (USD MN)
- Middle East & Africa Market Analysis (USD MN)
- Saudi Arabia Market Analysis (USD MN)
- UAE Market Analysis (USD MN)
- Israel Market Analysis (USD MN)
- South Africa Market Analysis (USD MN)
- Rest of Middle East and Africa Market Analysis (USD MN)
- Partnership/Collaboration/Agreement
- Mergers And Acquisiton
LIST OF FIGURES
- Research Scope of Benign Prostatic Hyperplasia (Bph) And Prostate Treatment Report
- Market Research Process
- Market Research Methodology
- Global Benign Prostatic Hyperplasia (Bph) And Prostate Treatment Market Size, by Region (USD MN)
- Porters Five Forces Analysis
- Market Attractiveness Analysis by Therapy
- Market Attractiveness Analysis by Region
- Value Chain Analysis
- Global Market Analysis by Therapy (USD MN)
- Drug Treatment Market by Geography (USD MN)
- Surgical Treatment Market by Geography (USD MN)
- Global Market by Revenue
- North America Market by Revenue
- Europe Market by Revenue
- Asia Pacific Market by Revenue
- Latin America Market by Revenue
- Middle East & Africa Market by Revenue
- Recent Development in Industry
- Company Market Share Analysis, 2020
* Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.
Related Categories
Healthcare
Buy Chapters or Sections
Avail customized purchase options to meet your exact research needs:
- Buy sections of this report
- Buy country level reports
- Request for historical data
- Request discounts available for Start-Ups & Universities
Objectives of Study
- Define and measure the global market
- Volume or revenue forecast of the global market and its various sub-segments with respect to main geographies
- Analyze and identify major market trends along with the factors driving or inhibiting the market growth
- Study the company profiles of the major market players with their market share
- Analyze competitive developments